Retro Biosciences
Develops therapies for longevity via cellular rejuvenation, autophagy, and plasma-inspired treatments.
Website: https://retro.bio
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Retro Biosciences |
| Tagline | Develops therapies for longevity via cellular rejuvenation, autophagy, and plasma-inspired treatments |
| Headquarters | San Francisco, California |
| Founded | 2021 |
| Stage | Series A |
| Industry | Healthtech / Biotech |
| Technology | Biotech and Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding Label | $100M+ |
| Total Disclosed | ~$180,000,000 confirmed seed; an additional ~$1B round reported but unconfirmed [SiliconANGLE, January 2025] |
Links
PUBLIC
- Website: https://www.retro.bio
- Pipeline: https://www.retro.bio/pipeline
- Careers: https://www.retro.bio/careers
- LinkedIn: https://www.linkedin.com/company/retro-biosciences
Executive Summary
PUBLIC
Retro Biosciences is a San Francisco biotech founded in 2021 that is pursuing one of the most ambitious targets in medicine: extending healthy human lifespan by roughly a decade through cellular rejuvenation, autophagy enhancement, and plasma-inspired therapeutics [MIT Technology Review, March 2023] [longevity.technology]. The company drew unusually broad attention in 2023 when OpenAI chief executive Sam Altman disclosed a personal $180 million commitment, an outsized seed by biotech norms and notable for being a single-investor check rather than a syndicate [MIT Technology Review, March 2023]. Retro has since moved from platform-building into the clinic, commencing a first-in-human Phase 1 trial of RTR242, a small-molecule autophagy promoter targeted at Alzheimer's disease, at an early-phase unit in Adelaide, Australia [Fight Aging!, January 2026] [longevity.technology]. The founding team is led by chief executive Joe Betts-LaCroix, alongside Sheng Ding and Matt Buckley, with Betts-LaCroix serving as the company's public face on scientific strategy [MIT Technology Review, March 2023] [lifespan.io]. In May 2024 the company announced an $85 million manufacturing partnership with Multiply Labs to industrialize cell therapy production for age-related disease, signalling a parallel bet on supply-side infrastructure as well as discovery [Business Wire, May 2024]. Reporting in January 2025 indicated Altman was anchoring a roughly $1 billion follow-on, which if confirmed would place Retro among the best-capitalized longevity programs globally [SiliconANGLE, January 2025]. Over the next 12 to 18 months, the readouts to track are RTR242's safety and pharmacodynamic data, any disclosed partner-program advancement on the cell-reprogramming and plasma-fraction pillars, and confirmation of the reported billion-dollar round.
Data Accuracy: GREEN -- Confirmed by MIT Technology Review, Business Wire, and longevity.technology.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A (post-seed, pre-clinical to Phase 1) |
| Business Model | Therapeutics development (pipeline-driven) |
| Industry / Vertical | Healthtech / Longevity Biotech |
| Technology Type | Small molecules, cellular reprogramming, plasma-inspired therapeutics |
| Geography | North America (SF Bay Area) with Australian clinical operations |
| Growth Profile | Venture Scale, capital-intensive |
| Founding Team | Joe Betts-LaCroix (CEO), Sheng Ding, Matt Buckley |
| Funding | ~$180M confirmed seed; ~$1B round reported [SiliconANGLE, January 2025] |
Company Overview
PUBLIC
Retro Biosciences was incorporated in 2021 in San Francisco around an explicit, quantified mission: add ten years of healthy life to the human lifespan [longevity.technology]. That framing, more concrete than most longevity company manifestos, came directly from chief executive Joe Betts-LaCroix, a serial entrepreneur and physicist-turned-biotech founder who had previously co-founded the small-server company OnLogic. Co-founders Sheng Ding and Matt Buckley brought, respectively, a chemistry-led cellular reprogramming background and operational biotech experience [MIT Technology Review, March 2023]. The company spent its earliest years in relative quiet, assembling laboratory operations and building out the three scientific pillars that still anchor its pipeline: partial cellular reprogramming, autophagy enhancement, and plasma-derived or plasma-inspired interventions [Crunchbase] [longevity.technology].
The company's public profile changed sharply in March 2023 when MIT Technology Review revealed that Sam Altman had personally placed $180 million into Retro, the entirety of the disclosed seed round, putting the company on a footing closer to a Series B by capital but still pre-clinical by program maturity [MIT Technology Review, March 2023]. Subsequent milestones have come at a measured cadence. In May 2024 Retro and Multiply Labs disclosed an $85 million partnership to scale robotic, automated cell therapy manufacturing aimed at age-related diseases, an unusually early bet on production infrastructure for a company without an approved product [Business Wire, May 2024]. In January 2025, SiliconANGLE and others reported that Altman was leading a roughly $1 billion additional financing, though that round has not been independently confirmed by the company at the time of writing [SiliconANGLE, January 2025] [medicalstartups.org].
The most consequential operational milestone to date came in early 2026, when Retro initiated a first-in-human Phase 1 trial for RTR242, a small-molecule autophagy promoter, at a specialized early-phase clinical unit in Adelaide, Australia [Fight Aging!, January 2026] [longevity.technology]. The choice of Australia for first-in-human work is consistent with broader industry practice: faster ethics review, cost advantages, and access to the R&D tax incentive. The trial is described as a randomized, double-blind, placebo-controlled study in healthy volunteers, the standard Phase 1 architecture for safety and pharmacokinetic characterization [Fight Aging!, January 2026].
Data Accuracy: GREEN -- Confirmed by MIT Technology Review, Business Wire, and longevity.technology.
Product and Technology
MIXED
Retro's pipeline is organized around three scientific programs rather than a single asset, which is unusual for a company of its stage and reflects the platform-style ambition described by management [Crunchbase] [longevity.technology]. The first pillar, partial cellular reprogramming, builds on Yamanaka-factor research that has shown the ability to reset epigenetic markers of cellular age in laboratory models; this is also the conceptual territory occupied by Altos Labs and NewLimit, making it a competitive but scientifically validated frontier. The second pillar, autophagy enhancement, targets the cellular waste-clearance process whose decline is implicated in neurodegeneration and other age-related conditions [Fight Aging!, January 2026]. The third, plasma-inspired therapeutics, draws on parabiosis literature suggesting that factors in young blood can have rejuvenating effects, and aims to identify and produce specific therapeutic fractions rather than relying on whole-plasma transfusion [longevity.technology] [Crunchbase].
The most concrete product disclosure to date is RTR242, a small-molecule therapy designed to restore lysosomal function and boost autophagic flux, with an initial indication in Alzheimer's disease [Fight Aging!, January 2026]. The mechanistic premise is that restoring neuronal autophagy can clear aggregating proteins (amyloid beta, tau, alpha-synuclein) that current antibody-based Alzheimer's drugs target downstream rather than upstream. The Phase 1 program in Adelaide is the company's first regulated clinical activity and is the single most important near-term milestone for outside observers, since it converts platform claims into a dose, a safety profile, and (potentially) pharmacodynamic biomarkers [Fight Aging!, January 2026] [longevity.technology].
On the manufacturing side, the May 2024 partnership with Multiply Labs is intended to apply robotic automation to cell therapy production, an explicit attempt to address the cost-of-goods problem that has constrained the commercial viability of autologous cell therapies in oncology and could plausibly bottleneck cell-based longevity interventions [Business Wire, May 2024]. CEO Joe Betts-LaCroix has also discussed AI-driven approaches to protein engineering in public interviews, framing computational tools as a multiplier on the wet-lab pipeline rather than a separate product line [lifespan.io]. The full technology stack underlying these programs has not been publicly itemized.
Data Accuracy: GREEN -- Confirmed by Fight Aging!, Business Wire, and longevity.technology.
Market Research and Opportunity
PUBLIC
Longevity has shifted in the last five years from a fringe biotech theme to one of the most heavily capitalized scientific frontiers, driven by aging demographics, the maturation of cellular reprogramming science, and a willingness among technology billionaires to fund moonshot biology personally rather than through conventional venture funds.
The headline market figure most often associated with Retro is a $610 billion longevity market, cited by a business-model template publication that does not itself trace the figure to a primary research firm [businessmodelcanvastemplate.com]. Investors should treat that number as directional rather than authoritative. More defensible market anchors come from looking at the addressable indications Retro is targeting. Alzheimer's disease alone, the initial indication for RTR242, is a market where Biogen and Eisai's Leqembi and Eli Lilly's Kisunla have established meaningful pricing precedent, and where analyst consensus places multi-billion-dollar peak-sales potential on disease-modifying therapies. Cell therapy for age-related disease, the indication area underlying the Multiply Labs partnership, sits adjacent to the autologous CAR-T market, which has been valued in the high single-digit billions and is growing at double-digit rates (analogous market).
| Market reference | Figure | Source |
|---|---|---|
| Aggregate longevity market | $610B | [businessmodelcanvastemplate.com] |
| Multiply Labs manufacturing partnership | $85M | [Business Wire, May 2024] |
| Reported follow-on round | ~$1B | [SiliconANGLE, January 2025] |
The $610 billion figure is the most cited and the least verifiable; the $85 million partnership and the reported billion-dollar round are the more meaningful proxies for how the capital markets are pricing the bet. Demand-side tailwinds are real and well documented in adjacent reporting: the global population aged 65 and over is projected to roughly double by 2050, healthspan-extension framing has gained traction with regulators considering aging as a treatable condition, and the FDA's recent willingness to approve modestly-effective Alzheimer's drugs signals that even partial disease-modification clears the commercial bar.
The regulatory backdrop is the largest swing factor. Aging itself is not currently an FDA-approved indication, which forces longevity companies to enter the clinic through specific age-related diseases (Alzheimer's, sarcopenia, fibrosis, immune decline) rather than aging as a whole. Retro's RTR242 strategy of targeting Alzheimer's first is consistent with that constraint and is the same approach taken by most credible longevity-adjacent programs. A secondary macro force worth flagging: the cost of capital for pre-revenue biotech has roughly doubled since 2021, which makes the reported Altman-led billion-dollar round, if confirmed, a meaningful counter-cyclical signal [SiliconANGLE, January 2025].
Data Accuracy: YELLOW -- TAM figure single-sourced; partnership and round size corroborated by Business Wire and SiliconANGLE.
Competitive Landscape
MIXED
Retro is competing in a small field of well-capitalized cellular-rejuvenation companies, with the distinguishing question being not whether the science works but which programs reach the clinic first and with what safety profile.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Retro Biosciences | Three-pillar platform: reprogramming, autophagy, plasma-inspired | Phase 1 (RTR242); ~$180M confirmed, ~$1B reported | First clinical asset in autophagy-promoter class targeting Alzheimer's | [Fight Aging!, January 2026] [SiliconANGLE, January 2025] |
| Altos Labs | Cellular reprogramming research institute model | Reported $3B+ launch funding | Largest scientific roster in the category, including Nobel laureates | [MIT Technology Review, March 2023] |
| NewLimit | Reprogramming-focused therapeutics, machine-learning driven | Series B reported | Coinbase CEO Brian Armstrong as anchor backer; ML-first discovery stack | [MIT Technology Review, March 2023] |
The segment splits cleanly into three groups. The first is the reprogramming-focused cohort (Altos, NewLimit, Retro on its first pillar) attempting to use partial expression of Yamanaka factors to restore youthful cellular function. Altos is the capital and talent leader by a wide margin but has been deliberately slow to disclose clinical timelines. NewLimit is leaner and more software-forward. Retro's edge in this group is breadth across three mechanistically distinct pillars and a willingness to move into the clinic earlier with a small-molecule rather than a cell therapy. The second group is the geroscience small-molecule cohort, including companies pursuing senolytics, mTOR modulators, and NAD+ pathway drugs; this group is closer to the clinic but is competing for the same age-related disease indications. The third is the plasma and young-blood-factor companies, a smaller but persistent cohort that overlaps with Retro's third pillar.
Retro's most defensible edge today is the combination of capital depth and clinical momentum. Most longevity peers are either deeply capitalized but still in discovery (Altos) or in the clinic but thinly funded; Retro is one of the few with both, particularly if the reported billion-dollar round materializes [SiliconANGLE, January 2025]. The Multiply Labs partnership is also a meaningful differentiator, because it begins to address cost-of-goods on the cell therapy side before the company has a candidate in the clinic, suggesting management is sequencing infrastructure investment ahead of need rather than after [Business Wire, May 2024]. The durability of these advantages is mixed: capital depth is perishable in biotech, where a single Phase 1 readout can reset the financing market overnight; the manufacturing partnership is more durable because automation expertise compounds.
The most plausible exposure is on the reprogramming pillar, where Altos's roster and budget are simply larger and where the first credible clinical translation will set the category standard. Retro is also exposed on the Alzheimer's competitive front, where established players (Biogen, Eisai, Lilly) own the commercial channel and where a small-molecule autophagy enhancer will need to clear a high bar to displace antibody-based standards of care. An 18-month scenario: Retro is the winner if RTR242 produces a clean Phase 1 safety profile and an interpretable autophagy biomarker by mid-2026, which would give it the first credible clinical asset in the autophagy class. Retro is the loser if RTR242 shows hepatotoxicity or off-target autophagy effects, which would force a pipeline reset while better-funded reprogramming peers continue to build.
Data Accuracy: YELLOW -- Competitor positioning confirmed; relative funding figures partially based on press reports.
Opportunity
PUBLIC
If Retro converts even one of its three pillars into a marketed therapy, the prize is on the order of a category-defining biotech franchise; if it converts two, it becomes the platform that the rest of the longevity field is benchmarked against.
The headline opportunity is to become the first integrated longevity therapeutics company with both an approved disease-modifying drug and a credible pipeline of mechanistically distinct follow-ons. The cited evidence makes that outcome reachable rather than aspirational on three counts: RTR242 is now in actual human dosing rather than discovery [Fight Aging!, January 2026]; the Multiply Labs partnership signals manufacturing readiness for the cell therapy pillar [Business Wire, May 2024]; and the capital base, particularly if the reported billion-dollar round closes, is sufficient to fund parallel Phase 2 programs without forced near-term financing [SiliconANGLE, January 2025]. The category that Retro could plausibly define is autophagy modulation as a therapeutic class, in the same way that PD-1 inhibition defined modern oncology.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Autophagy class leader | RTR242 establishes a clean safety profile and a measurable pharmacodynamic biomarker; Retro becomes the reference compound for autophagy enhancement across multiple indications | Positive Phase 1 readout from the Adelaide trial in 2026 [Fight Aging!, January 2026] | Trial is randomized, double-blind, placebo-controlled, and the mechanism is supported by published lysosomal biology |
| Reprogramming platform winner | Retro's reprogramming pillar delivers an IND-ready candidate before larger-funded peers, validating the three-pillar strategy | Disclosed partner-program data or an IND filing within 18 months | Capital base is sufficient to run reprogramming and small-molecule work in parallel [SiliconANGLE, January 2025] |
| Manufacturing-led cell therapy entrant | The Multiply Labs partnership produces a cost structure that makes age-related cell therapy commercially viable, attracting pharma partnership interest | Demonstrated automated cell therapy production at scale | $85M committed and the partnership was announced as production-oriented from inception [Business Wire, May 2024] |
What compounding looks like in Retro's case is less a software-style network effect and more a pipeline-and-platform flywheel. Each clinical asset that clears Phase 1 raises the company's cost of capital advantage versus discovery-stage peers, which in turn allows it to in-license or originate the next asset on better terms. The Multiply Labs partnership is an early example of this dynamic in operation: by securing dedicated automated manufacturing capacity now, Retro reduces the marginal cost and time of each subsequent cell therapy program it develops [Business Wire, May 2024]. On the discovery side, public commentary from CEO Joe Betts-LaCroix on AI-assisted protein engineering suggests the company sees computational tooling as a similar compounding mechanism on the molecule-design side [lifespan.io].
The size of the win is best framed against named comparables. Vertex Pharmaceuticals, which built its franchise around a single mechanism (CFTR modulation in cystic fibrosis) before expanding, trades at a market capitalization in the high tens of billions of dollars. Moderna's market capitalization peaked above $100 billion on the strength of a single platform readout. If Retro's autophagy class scenario plays out and RTR242 delivers credible Phase 2 disease modification in Alzheimer's, a comparable mid-cap biotech outcome is within the realm of plausibility (scenario, not a forecast). Even a more modest outcome, in which Retro becomes an attractive acquisition target for a large pharmaceutical company seeking exposure to longevity biology, would imply a multi-billion-dollar enterprise value consistent with recent late-Phase Alzheimer's transactions.
Data Accuracy: YELLOW -- Scenarios are analyst-constructed; underlying milestones cited from Fight Aging!, Business Wire, and SiliconANGLE.
Sources
PUBLIC
[MIT Technology Review, March 2023] Sam Altman invested $180 million into a company trying to delay death | https://www.technologyreview.com/2023/03/08/1069523/sam-altman-investment-180-million-retro-biosciences-longevity-death/
[Business Wire, May 2024] Multiply Labs and Retro Biosciences Announce an $85 Million Partnership to Advance Cell Therapy Manufacturing for Age-Related Diseases | https://www.businesswire.com/news/home/20240514445088/en/Multiply-Labs-and-Retro-Biosciences-Announce-an-$85-Million-Partnership-to-Advance-Cell-Therapy-Manufacturing-for-Age-Related-Diseases
[SiliconANGLE, January 2025] Sam Altman reportedly backs $1B round for AI healthcare startup Retro Biosciences | https://siliconangle.com/2025/01/24/sam-altman-reportedly-backs-1b-round-ai-healthcare-startup-retro-biosciences/
[Fight Aging!, January 2026] Retro Biosciences Starts a Safety Trial for an Autophagy Promoter | https://www.fightaging.org/archives/2026/01/retro-biosciences-starts-a-safety-trial-for-an-autophagy-promoter/
[longevity.technology] Retro Bio commences first-in-human trial | https://longevity.technology/news/retro-bio-commences-first-in-human-trial/
[longevity.technology] Retro: A longevity biotech triple-threat? | https://longevity.technology/news/retro-a-longevity-biotech-triple-threat/
[Crunchbase] Retro Biosciences - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/retro-biosciences
[Crunchbase] Retro Biosciences - Contacts, Employees, Board Members, Advisors & Alumni | https://www.crunchbase.com/organization/retro-biosciences/people
[LinkedIn] Retro Biosciences | LinkedIn | https://www.linkedin.com/company/retro-biosciences
[businessmodelcanvastemplate.com] What is Brief History of Retro Biosciences Company? | https://businessmodelcanvastemplate.com/blogs/brief-history/retro-biosciences-brief-history
[lifespan.io] Joe Betts-Lacroix on Retro Bio and Its Recent AI Advancement | https://lifespan.io/news/joe-betts-lacroix-on-retro-bio-and-its-recent-ai-advancement/
[LNGFRM] Sam Altman-Backed Retro Biosciences Begins Human Trials for Aging Reversal | https://lngfrm.net/sam-altman-backed-retro-biosciences-begins-human-trials-for-aging-reversal/
[primewomen.com] Retro Biosciences: Looking to Give You Another Decade | https://primewomen.com/wellness/retro-biosciences/
[medicalstartups.org] Retro Biosciences (USA) Funding: $1.1B | https://www.medicalstartups.org/startup/retro/
[Retro Biosciences] Retro Bio Pipeline | https://www.retro.bio/pipeline
Articles about Retro Biosciences
- Retro Biosciences Is Putting an Autophagy Pill Into Healthy Volunteers in Adelaide — The San Francisco longevity startup, backed by Sam Altman, has moved its first Alzheimer's candidate RTR242 into a Phase 1 safety trial.